Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1).
Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1).
Clin Transl Radiat Oncol. 2020 Sep;24:99-101
Authors: Corbin KS, Breen WG, Strauss JB
Abstract
Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigilant of unexpected toxicities with newly approved therapies.
PMID: 32715108 [PubMed]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Corbin KS, Breen WG, Strauss JB Tags: Clin Transl Radiat Oncol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Dermatitis | Dermatology | HER2 | Herceptin | Toxicology